By Counterforce Health Team in Onivyde (irinotecan liposome) —

How to Get Onivyde (Irinotecan Liposome) Covered by Cigna in Ohio: Forms, Appeals, and Approval Timeline

Answer Box: Quick Path to Onivyde Coverage

Cigna requires prior authorization for Onivyde (irinotecan liposome) in Ohio. Most approvals need: metastatic pancreatic cancer diagnosis, prior gemcitabine or fluoropyrimidine failure, ECOG 0-2 performance status, and adequate organ function. Submit the Cigna Onivyde PA form via fax (855-840-1678) or CoverMyMeds. Standard review takes 5 business days; expedited reviews 24 hours if urgent. If denied, appeal within 180 days—Cigna's appeal overturn rate is 86% in Ohio.

First step today: Download the PA form and gather your oncology records showing prior therapy failure.

Table of Contents

  1. Do You Qualify for Onivyde Coverage?
  2. Required Documents and Submission
  3. If You're Possibly Eligible
  4. If You Don't Meet Criteria Yet
  5. When Your Request Gets Denied
  6. Ohio External Review Process
  7. Cost-Saving Resources
  8. FAQ

Do You Qualify for Onivyde Coverage?

Coverage at a Glance

Requirement What It Means Where to Find It Source
PA Required Yes, all plans Cigna formulary Cigna PA Forms
Diagnosis Metastatic pancreatic adenocarcinoma Pathology report, ICD-10 C25.9 Onivyde PA Form
Prior Therapy Gemcitabine or fluoropyrimidine failure Treatment records Cigna Coverage Policy
Performance Status ECOG 0-2 preferred Oncologist assessment Coverage Criteria
Appeal Deadline 180 days from denial Denial letter Ohio DOI

Eligibility Decision Tree

You're likely eligible if:

  • Diagnosed with metastatic pancreatic adenocarcinoma
  • Previously tried gemcitabine-based therapy with disease progression
  • ECOG performance status 0-2
  • Adequate liver, kidney, and bone marrow function

You're possibly eligible if:

  • First-line treatment candidate (NALIRIFOX regimen approved February 2024)
  • Prior irinotecan intolerance requiring liposomal formulation
  • Ampullary adenocarcinoma with prior therapy failure

Not yet eligible if:

  • No prior standard therapy attempted
  • ECOG performance status 3-4
  • Severe organ dysfunction

Required Documents and Submission

Step-by-Step: Fastest Path to Approval

  1. Download the PA Form (Prescriber)
  2. Gather Clinical Documentation (Patient + Clinic)
    • Pathology confirming metastatic pancreatic adenocarcinoma
    • Prior treatment records showing gemcitabine failure
    • Recent labs (CBC, CMP, performance status assessment)
    • Current imaging showing disease progression
  3. Complete Medical Necessity Letter (Prescriber)
    • Document prior therapy dates and outcomes
    • Include NCCN guideline reference for post-gemcitabine treatment
    • Specify proposed regimen (NALIRIFOX if first-line, or combination with 5-FU/LV)
  4. Submit via Preferred Channels
  5. Track Your Request
    • Standard review: 5 business days
    • Expedited review: 24 hours (requires clinical urgency attestation)
  6. Fill at Accredo Specialty Pharmacy
    • Cigna's preferred specialty pharmacy
    • J-code: J9205 for billing
Tip: Submit expedited requests for patients with rapidly progressing disease or those experiencing treatment delays that could affect outcomes.

If You're Possibly Eligible

First-Line NALIRIFOX Consideration

Since February 2024, Onivyde is FDA-approved for first-line metastatic pancreatic cancer as part of the NALIRIFOX regimen. If you haven't tried gemcitabine yet, discuss with your oncologist whether NALIRIFOX is appropriate based on:

  • Age and performance status
  • Comorbidities and organ function
  • Patient preference for aggressive vs. sequential therapy

Step Therapy Override Process

If Cigna requires you to try other treatments first, request a step therapy override by documenting:

  • Why standard options are inappropriate for your case
  • Clinical evidence supporting Onivyde as first choice
  • Risk of treatment delay on disease progression

Submit override requests using Cigna's formulary exception process with 2-day standard review.

If You Don't Meet Criteria Yet

Alternative Treatments to Discuss

While preparing for Onivyde approval, consider these options:

  • FOLFIRINOX: First-line alternative for fit patients
  • Gemcitabine + nab-paclitaxel: Standard first-line option
  • Clinical trials: May provide access to Onivyde or similar agents

Building Your Case for Exception

Document the following to strengthen future Onivyde requests:

  1. Treatment failures: Dates, doses, duration, and specific reasons for discontinuation
  2. Contraindications: Why standard alternatives aren't suitable
  3. Disease progression: Imaging and tumor markers showing advancement
  4. Quality of life impact: How current treatments affect daily functioning

When Your Request Gets Denied

Appeals Playbook for Cigna in Ohio

Appeal Level Timeline How to File Required Documents
Peer-to-Peer Review Request within 3 days Call provider services Clinical notes, guidelines
First Internal Appeal 180 days from denial Written request to Cigna Denial letter, medical records
Second Internal Appeal 60 days from first denial Written request Additional evidence
Ohio External Review 180 days from final denial Through Cigna to ODI Complete case file

Common Denial Reasons & How to Fix Them

Denial Reason How to Overturn
"Not medically necessary" Submit NCCN guidelines showing Onivyde as preferred post-gemcitabine
"Step therapy required" Document gemcitabine failure or contraindication to alternatives
"Off-label use" Provide FDA labeling showing approved indications
"Quantity limits exceeded" Justify dosing based on BSA and treatment protocol

Scripts for Common Situations

Patient calling Cigna customer service: "I'm calling about a prior authorization denial for Onivyde, PA reference number [X]. My oncologist says this is the standard treatment after gemcitabine failed. I'd like to request a peer-to-peer review and understand the appeal process."

Prescriber requesting peer-to-peer: "I'm requesting a peer-to-peer review for Onivyde PA denial. The patient has metastatic pancreatic adenocarcinoma with documented gemcitabine progression. This aligns with NCCN Category 1 recommendations. When can we schedule the clinical review?"

Ohio External Review Process

If Cigna upholds their denial after internal appeals, Ohio residents can request an independent external review through the Ohio Department of Insurance.

Key Ohio External Review Facts

  • No cost to patients
  • 180-day deadline from Cigna's final denial
  • 30-day decision for standard reviews
  • 72-hour decision for expedited reviews
  • 86% success rate for Cigna appeals in Ohio

How to Request External Review

  1. Submit request through Cigna (not directly to ODI)
  2. Include all documentation: denial letters, medical records, prescriber letter
  3. Request expedited review if delay would seriously endanger health
  4. Contact ODI consumer hotline: 800-686-1526 for questions

The Independent Review Organization (IRO) assigned to your case will include medical experts familiar with oncology treatments. Their decision is binding on Cigna.

Cost-Saving Resources

Financial Assistance Options

Ipsen Patient Support Program

  • Copay assistance for commercially insured patients
  • Free drug program for uninsured/underinsured
  • Contact: Onivyde.com patient resources (verify current programs)

Foundation Grants

  • Leukemia & Lymphoma Society (covers pancreatic cancer)
  • CancerCare Financial Assistance
  • Patient Advocate Foundation

Ohio-Specific Resources

  • Ohio Cancer Patient Navigator Program
  • UHCAN Ohio for insurance advocacy: (verify contact information)

Frequently Asked Questions

How long does Cigna prior authorization take for Onivyde in Ohio? Standard reviews take 5 business days; expedited reviews 24 hours with clinical urgency documentation.

What if Onivyde is non-formulary on my Cigna plan? Request a formulary exception with clinical justification. Cigna reviews these in 2 business days for standard cases.

Can I appeal if I'm on a Medicare Advantage plan? Yes, the same appeal rights apply. Medicare Advantage appeals have an 86% success rate with Cigna.

Does step therapy apply if I failed gemcitabine outside Ohio? No, prior therapy failure anywhere should satisfy step therapy requirements if properly documented.

What's the difference between peer-to-peer and formal appeal? Peer-to-peer is an informal clinical discussion; formal appeals create a written record and lead to external review rights.

How do I get expedited review for urgent cases? Your oncologist must attest that delays would seriously jeopardize your health or ability to regain maximum function.

From Our Advocates

In our experience helping patients navigate Onivyde approvals, the most successful cases include comprehensive documentation of prior therapy failure with specific dates, doses, and reasons for discontinuation. One common issue we see is incomplete performance status documentation—make sure your oncologist clearly states your ECOG score and functional capacity. While we can't guarantee outcomes, thorough initial submissions significantly reduce denial rates and appeal timelines.

Counterforce Health helps patients and clinicians turn insurance denials into successful appeals through evidence-backed strategies tailored to each payer's specific requirements. Our platform analyzes denial letters and plan policies to create targeted rebuttals that speak directly to insurers' criteria, improving approval rates for specialty medications like Onivyde. Learn more about our approach to streamlining the prior authorization process.

The complexity of prior authorization for specialty oncology drugs often overwhelms both patients and clinicians. Counterforce Health addresses this challenge by providing the clinical evidence and procedural expertise needed to navigate payer requirements effectively, reducing the administrative burden while improving patient access to life-saving treatments.

Sources & Further Reading

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Always consult with your healthcare provider about treatment decisions. Insurance coverage varies by plan and individual circumstances. Verify current forms, deadlines, and procedures with your insurer and the Ohio Department of Insurance before taking action.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.